Pfizer pays Starna Therapeutics $330 million upfront to license three preclinical in vivo CAR-T programs for autoimmune diseases in a deal worth up to $2.63 billion plus royalties.
Written By: Creola Gonsalves, MS Biotech
Reviewed By: Pharmacally Editorial Team
Pfizer has entered an exclusive licensing agreement with Starna Therapeutics to advance three preclinical in vivo chimeric antigen receptor T-cell (CAR-T) programmes targeting autoimmune diseases. The agreement includes a $330 million upfront payment and potential milestone payments of up to $2.3 billion, plus royalties on net sales of approved products.
Three Pre-IND CAR-T Programs Target Autoimmune Diseases
Under the agreement, Pfizer obtains exclusive rights outside Greater China to develop, manufacture and commercialize three in vivo CAR-T programmes currently at the pre-investigational new drug (pre-IND) stage. The programmes focus on autoimmune diseases, where existing treatments do not adequately control disease activity or provide sufficient benefit for some patients.
Unlike conventional ex vivo CAR-T approaches, which generally require T cells to be collected, genetically modified outside the body and subsequently reinfused, in vivo CAR-T approaches seek to generate CAR-expressing immune cells directly inside the patient.
This approach could simplify manufacturing and treatment logistics by eliminating the need for individualized cell collection and ex vivo engineering. However, its clinical feasibility will depend on achieving targeted delivery, sufficient CAR expression, therapeutic activity and an acceptable safety profile.
Starna’s Targeted LNP-RNA Platform Powers In Vivo Delivery
Starna’s proprietary platform combines targeted lipid nanoparticle (LNP) delivery with RNA technology. LNPs transport RNA-based genetic instructions into cells, potentially enabling immune cells to express chimeric antigen receptors directly within the body.
In autoimmune diseases, CAR-T therapies could potentially target specific immune cell populations involved in disease pathology. However, the specific CAR targets, RNA constructs, delivery mechanisms and intended autoimmune indications for Starna’s three programmes have not been disclosed.
Pfizer Secures Broader Technology and Territorial Options
Beyond the three licensed programmes, Pfizer receives rights to use Starna’s proprietary in vivo CAR-T technology across inflammation and immunology and oncology.
The agreement also includes options to exclusively license additional compounds generated through a separate research collaboration. Pfizer further holds options to expand its territorial rights to include Greater China for individual compounds and products licensed under the agreement.
U.S. Manufacturing and Leadership Perspectives
Pfizer will lead clinical development outside Greater China and plans to manufacture finished drug products for the initial clinical trials at its facilities in the United States. The company will also retain sole and exclusive commercialization control outside Greater China for all licensed products.
Michael Vincent, M.D., Ph.D., Pfizer’s Chief Inflammation and Immunology Officer, highlighted the potential of in vivo CAR-T approaches for autoimmune diseases, particularly for patients whose treatment options remain limited. He also identified Pfizer’s experience in RNA-based medicine development and global manufacturing as important capabilities for advancing these programmes.
Starna CEO Rongkuan Hu, Ph.D., emphasized the company’s targeted LNP delivery platform and RNA technology as the scientific foundation of the collaboration.
$2.63 Billion Deal Expands Pfizer’s Cell Therapy Strategy
Under the financial terms, Starna will receive $330 million upfront and is eligible for up to $2.3 billion in development and commercial milestone payments, bringing the maximum potential upfront and milestone consideration to $2.63 billion. Starna will also receive royalties on net sales of approved products.
The agreement expands Pfizer’s RNA-based therapeutic strategy into in vivo immune cell engineering. It gives the company access to Starna’s existing delivery technology and multiple early-stage programmes, potentially accelerating its entry into this emerging area of cell therapy.
Preclinical Risks and Upcoming Development Milestones
All three licensed autoimmune programmes remain at the pre-IND stage. Their clinical potential, safety profile, therapeutic durability and development timelines have yet to be established in human studies.
The next development milestones will include candidate advancement, IND-enabling studies and regulatory submissions before clinical evaluation can begin. Pfizer’s ability to translate Starna’s targeted RNA delivery technology into reproducible CAR-T activity with an acceptable safety profile will determine the longer-term value of the collaboration.
Reference
Pfizer Enters into Exclusive Licensing Agreement with Starna Therapeutics for Autoimmune Diseases, Pfizer, 18 November 2026
About the Writer
Creola Gonsalves (Linkedin) is an M.S. Biotechnology postgraduate with a strong interest in clinical research, evidence interpretation, and healthcare writing, with a focus on translating life-science knowledge into meaningful real-world insights.
She is trained in Good Clinical Practice (GCP), clinical research principles, and critical interpretation of randomized clinical trials, with certifications from NIH and Stanford University.
Her research background in biotechnological applications and microbial research strengthens her ability to understand scientific evidence and develop clear, accurate, and research-driven healthcare content.
